Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could inflammation explain why some kids with ADHD don't improve on medication?

NCT ID NCT07417878

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether children with ADHD have different levels of inflammation and nutrition markers compared to children without ADHD. Researchers will follow 80 children aged 7 to 17 for one year to see if these markers affect how well they respond to common ADHD medication. The goal is to better understand the biology behind ADHD and find ways to personalize treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

ADHD Group (Cases) - Inclusion Criteria: * Children or adolescents aged 7 to 17 years. * Meet DSM-5 diagnostic criteria for Attention-Deficit/Hyperactivity Disorder (ADHD), assessed using the K-SADS interview. * Currently treated with psychostimulant medication. * Stabilized on psychostimulant treatment for at least one month prior to inclusion. * Signed informed consent obtained from parents or legal guardians. * Assent obtained from the minor participant. * Affiliation with a national health insurance system. Control Group (Typically Developing Peers) - Inclusion Criteria: * Children or adolescents aged 7 to 17 years without any diagnosed mental disorder. * Age- and sex-matched with the ADHD group. * Signed informed consent obtained from parents or legal guardians. * Assent obtained from the minor participant. * Affiliation with a national health insurance system. ADHD Group (Cases) - Exclusion Criteria: * Presence of a progressive neurological disorder, intellectual developmental disorder, or clinically significant suicide risk. * Presence of an immunological or chronic inflammatory disease. * Inability to comply with medication-free periods of at least two weeks. * Absence of parental consent. * Absence of assent from the minor participant. * Participation in another clinical study with an ongoing exclusion period. Control Group (Typically Developing Peers) - Exclusion Criteria: * Presence of an immunological or chronic inflammatory disease. * Absence of parental consent. * Absence of assent from the minor participant. * Participation in another clinical study with an ongoing exclusion period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD - attention deficit disorder with hyperactivity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder Inflammation neurodevelopmental disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD - attention deficit disorder with hyperactivity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.